Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

John Hopkins

- PMLiVE

MHRA approves second COVID-19 antibody treatment

Preclinical data for GSK and Vir’s Xevudy suggests it retains activity against Omicron and all other variants of concern

- PMLiVE

Sandoz completes acquisition of GSK’s cephalosporin business

The acquisition confirms Sandoz’ commitment to antibiotics, following the announcement of further investment plans for European-based manufacturing network

dengue fever mosquito

WHO has recommended GSK’s malaria vaccine for children

This is the first and only malaria vaccine to have been shown in pivotal long-term clinical trials to significantly reduce malaria in children

- PMLiVE

GSK/SK bioscience COVID-19 vaccine to enter phase 3 trial

The study will be one of the first global phase 3 trials to compare two different COVID-19 vaccine candidates

- PMLiVE

US demand for COVID-19 antibody treatments rising fast

With the ‘fourth wave’ of COVID-19 in the US, Regeneron and GSK report high demand for their monoclonal antibody treatments

- PMLiVE

GSK/Merck KGgA cancer drug fails in third trial

Fusion protein, bintrafusp alfa – the centrepiece of the 2019 GSK/Merck partnership – has failed to meet its latest trial endpoint and the trial is to be discontinued

Roche Basel Switzerland

FDA approval for Roche diagnostic solid tumour test

Test will identify which patients could benefit from GSK immunotherapy.

Roche Basel Switzerland

FDA approval for Roche diagnostic solid tumour test

Test will identify which patients could benefit from GSK immunotherapy.

dengue fever mosquito

BioNTech to use mRNA technology to develop a ‘highly effective’ malaria vaccine

The company aims to develop a vaccine candidate and also boost mRNA manufacturing capabilities on the African continent

- PMLiVE

GSK, Vir’s sotrovimab cuts hospitalisation and death risk by 79% in COVID-19 outpatients

Final efficacy analysis confirms previous positive findings from interim analysis

- PMLiVE

EMA concludes GSK, Vir’s mAb can be used to treat high-risk COVID-19 patients

Recommendations can be used to support national advice prior to marketing authorisation

dengue fever mosquito

Oxford University’s malaria vaccine is 77% effective

First vaccine to meet WHO-specified efficacy goal of 75%, says research team

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links